The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A first-in-human study of DYP688, an antibody drug conjugate delivering a direct Gq/11 inhibitor, in patients with metastatic uveal melanoma (MUM) and other GNAQ/11 mutant melanomas.
 
Matteo Carlino
Honoraria - Bristol-Myers Squibb; MSD; Novartis
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Eisai; IDEAYA Biosciences; Innovent Biologics; Medison; Medison; Merck Serono; Moderna Therapeutics; MSD; Nektar; Novartis; OncoSec; Pierre Fabre; QBiotics; Regeneron; Roche; Sanofi
 
Reinhard Dummer
Honoraria - Amgen; Bristol-Myers Squibb; Catalym; MaxiVax ; MSD; Novartis; Oncobit; Pfizer; Pierre Fabre; Regeneron; Roche; Sanofi; Second Genome; Simcere; Sun Pharma; T3 Pharmaceuticals; Takeda
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Catalym; MaxiVax ; MSD; Novartis; Oncobit; Pfizer; Pierre Fabre; Regeneron; Roche; Sanofi; Simcere; Sun Pharma; T3 Pharmaceuticals; Takeda
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
 
Tanja Gromke
No Relationships to Disclose
 
Jessica Hassel
Honoraria - Bristol Myers Squibb Foundation; Delcath Systems; Immunocore; MSD; Novartis; Pierre Fabre; Sanofi; Sun Pharma
Consulting or Advisory Role - BMS GmbH & Co. KG (Inst); Immunocore (Inst); MSD (Inst); Novartis (Inst); Philogen (Inst); Pierre Fabre (Inst); Sanofi Aventis GmbH (Inst); Sun Pharma
Research Funding - Agenus (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Genmab (Inst); immatics (Inst); Immunocore (Inst); IO Biotech (Inst); Iovance Biotherapeutics (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Philogen (Inst); Pierre Fabre (Inst); Regeneron (Inst); Replimune (Inst); Sanofi (Inst); Sanofi Aventis GmbH (Inst); Sun Pharma (Inst)
Travel, Accommodations, Expenses - BMS GmbH & Co. KG; Iovance Biotherapeutics; Sun Pharma
 
Ellen Kapiteijn
Consulting or Advisory Role - Delcath Systems (Inst); Immunocore (Inst); Lilly (Inst)
Research Funding - BMS (Inst); Delcath Systems (Inst); Novartis (Inst); Pierre Fabre (Inst)
 
Damien Kee
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; Medison; MSD; Novartis
 
Sophie Piperno-Neumann
Consulting or Advisory Role - Deciphera; Immunocore; Replimune
Research Funding - Foghorn Therapeutics (Inst); MSD (Inst)
Travel, Accommodations, Expenses - Deciphera; Immunocore; PharmaMar
 
Egle Ramelyte
Honoraria - BMS GmbH & Co. KG; Galderma; Lilly; MSD; Pierre Fabre; Sanofi
Consulting or Advisory Role - Amgen; Kyowa Kirin International; Sanofi/Regeneron
Speakers' Bureau - BMS GmbH & Co. KG; MSD; Sanofi/Regeneron
Research Funding - Amgen (Inst); Sanofi/Regeneron (Inst)
Patents, Royalties, Other Intellectual Property - Contribution to UpToDate chapter update for Superficial acitic porokeratosis.
Travel, Accommodations, Expenses - Amgen; Pierre Fabre; Sanofi
 
Alexander Shoushtari
Consulting or Advisory Role - Erasca, Inc; Immunocore
Research Funding - Bristol-Myers Squibb (Inst); IDEAYA Biosciences (Inst); Immunocore (Inst); Iovance Biotherapeutics (Inst); Linnaeus Therapeutics (Inst); Merck (Inst); Mural Oncology (Inst); Novartis (Inst); Obsidian Therapeutics (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
 
Ryan Sullivan
Consulting or Advisory Role - BridGene Biosciences; Bristol-Myers Squibb; Marengo Therapeutics; Merck; Novartis; Pfizer; Replimune
Research Funding - Aeglea Biotherapeutics (Inst); Amgen (Inst); Asana Biosciences (Inst); BeiGene (Inst); BioMed Valley Discoveries (Inst); Compugen (Inst); Deciphera (Inst); Georgimmune (Inst); Lilly (Inst); Marengo Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Neon Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Strategia (Inst); Strategia (Inst); Synthekine (Inst); Viralytics (Inst)
 
Alexander Wei
Research Funding - IDEAYA Biosciences (Inst); Novartis (Inst); Regeneron (Inst)
 
Anne-Marie Duggan
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Mary Ising
Employment - Novartis
 
Pedro Milanez-Almeida
Employment - Novartis
 
Thiruvamoor Ramkumar
Employment - Novartis
 
Aimee Reynolds
Employment - Novartis
 
Sherif Sharaby
Employment - Novartis
 
Padmaja Yerramilli-Rao
Employment - Novartis
 
Emiliano Calvo
Employment - HM Hospitales; START
Leadership - BeiGene; European Organisation for Research and Treatment of Cancer (EORTC); Merus NV; Novartis; PharmaMar; Sanofi; START
Stock and Other Ownership Interests - Oncoart Associated; START
Honoraria - HM Hospitales
Consulting or Advisory Role - Adcendo; Amunix; Anaveon; AstraZeneca/MedImmune; Bristol-Myers Squibb; Chugai Pharma; Diaccurate; Elevation Oncology; Ellipses Pharma; Genmab; Janssen-Cilag; MonTa Biosciences; MSD Oncology; Nanobiotix; Nouscom; Novartis; OncoDNA; PharmaMar; Roche/Genentech; Servier; Syneos Health; T-Knife; TargImmune Therapeutics
Research Funding - START
Other Relationship - CRIS Cancer Foundation; Foundation PharmaMar; Investigational Therapeutics in Oncological Sciences